Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyIndolent LymphomasNeuro-OncologyT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMalignant MeningitisMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoblastic LymphomaNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Lymphoblastic LymphomaSubgroupB-ALLBCR-ABL positiveCD22+Leukemic MeningitisPh/BCR-ABL-T-ALLunfitICD10C79.3C82.-C82.7C82.9C83.1C83.3C83.5C83.7C84.6C91.0-C91.1-C91.5-MeSHBurkitt LymphomaLymphoma, Mantle-CellMeningeal CarcinomatosisPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaSequenceALL, Mini-hyperCVD/Inotuzumab Ozogamicin: Mini-hyperCVD (CYCL150/VNCR2/DEXA20)/INTZ(0.6/0.3)/RITU375, ALL/NHL, C1 (PID2098) -|- C2 (PID2097) -|- C3 (PID2099) -|- C4 (PID2097) -|- maint. (PID313)ALL,Ph/BCR-ABL+: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375/IMAT800, ALL/NHL, Ph/BCR-ABL+, C1 (PID2084) -|- C2 (PID2085) -|- C3 (PID2086) -|-C4 (PID2085) -|- C5 (PID2087) -|- C6 (PID2088) -|- C7 (PID2089) -|- C8 (PID2090) -|- Month 1-5 (PID2073) -|- Month 6 (PID2110) -|- Month 7 (PID2113) -|- Month 8-17 (PID2073) -|- Month 18 (PID2110) -|- Month 19 (PID2113) -|- Month 20-24 (PID2073)B-ALL/recurrent therapy: mini-hyperCVD (CYCL150/VNCR2/DEXA20)/INTZ(0.6/0.3)/RITU375, ALL/NHL, C1 (PID2098) -|- C2 (PID2097) -|- C3 (PID2099) -|- C4 (PID2097) -|- C1 (PID2117) -|- C2-4 (PID2118) -|- maint., Month 1-12 (PID2119) -|- maint., month 13-36 (PID2120)B-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, B-ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C5 (PID2063) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2074) -|- Month 7 (PID2061) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)BLIN(9/28), ALL, C1 (PID107) -|- C2-5 (PID68) -|- Maint. (PID313)GMALL-ALL - FrailGMALL-ALL - Frail Ph/BCR-ABL+GMALL 08/2013-ALL/LBL, 56 - 75GMALL 08/2013-ALL/LBL, 56 - 75, Ph/BCR-ABL+GMALL 08/2013-ALL/LBL 18 - 55GMALL 08/2013-ALL/LBL 18 - 55, Ph/BCR-ABL+GMALL 08/2013-B-ALL/NHL 2002 Regimen, 18 - 55GMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, B-ALL onlyGMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, NHL onlyIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)PRED60/DSTN140 - BLIN28/DSTN140, ALL (PID1679) -|- (PID1678)R-ICE (RITU375/ETOP100/CRBP635/IFOS3), Burkitt's Lymphoma, C1-2 (PID2223) -|- C3 (PID2224).T-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C4N (PID2083) -|- C5 (PID2063) -|- C5N (PID2083) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2083) -|- Month 7 (PID2083) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)ChemotherapyChemo-substanceAsparaginaseBlinatumomabCarboplatinCladribineClofarabinCyclophosphamideCytarabineDasatinibDaunorubicinDexamethasoneDoxorubicinEtoposideFludarabineIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateMethylprednisoloneNelarabineNilotinibPeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceAsparaginaseBlinatumomabCarboplatinCladribineClofarabinCyclophosphamideCytarabineDasatinibDaunorubicinDexamethasoneDoxorubicinEtoposideFludarabineIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateMethylprednisoloneNelarabineNilotinibPeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceAsparaginaseBlinatumomabCarboplatinCladribineClofarabinCyclophosphamideCytarabineDasatinibDaunorubicinDexamethasoneDoxorubicinEtoposideFludarabineIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateMethylprednisoloneNelarabineNilotinibPeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceAsparaginaseBlinatumomabCarboplatinCladribineClofarabinCyclophosphamideCytarabineDasatinibDaunorubicinDexamethasoneDoxorubicinEtoposideFludarabineIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateMethylprednisoloneNelarabineNilotinibPeg asparaginasePrednisoloneRituximabVincristineVindesineNo. Substances12345678 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidValaciclovirSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidValaciclovirSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidValaciclovirSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidValaciclovirNo. Substances12345678910111213141516Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseautologous stem cell transplantationConsolidationInductionMaintenancePre-phaseReinductionSalvageseveral possibleTherapy intentioncurativecurative or palliativedisease controlpalliativeRisksAnemia Hb below 8g/dlAstheniaBleedingCardiotoxicityCMV Infection (asympt. + sympt.)ConstipationCytokine Release SyndromeDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHepatotoxicityHyperbilirubinemiaHyperglycemiaHypertensionHypokalemiaIncrease AminotransferasesInfectionsInfusion ReactionMucositisMyalgiasNeuropathyNeurotoxicityNeutropeniaOral MucositisPleural EffusionPneumoniaPyrexiaRashRenal FailureSeizuresSepsisThrombocytopenia below 50 000/µlTumor Lysis SyndromeVOD/SOSVomiting only studiesPublicationAuthorChalandon YDavies ADeAngelo DJFoà RGriffin TCGökbuget DGökbuget NGökbuget N, Hartog CHoelzer DJabbour EKantarjian HKopmar NLuskin MRMaude SLRausch CRausch CRZeidan AMDiseaseAkute lymphatische Leukämie, 18-55 JahreAkute lymphatische Leukämie, 56-75 JahreAkute lymphatische Leukämie, 56-75 Jahre, Ph/BCR-ABL+Akute lymphatische Leukämie, B/T lymphoblastisches LymphomAkute lymphatische Leukämie, lymphoblastische Lymphome, 18-55 JahreAkute lymphatische Leukämie, lymphoblastische Lymphome, 56-75 JahreAkute lymphatische Leukämie, lymphoblastische Lymphome, Therapieversagen oder MRD-Persistenz nach Konsolidation I,18-55 JahreAkute lymphatische Leukämie, Rezidiv nach der ErstlinientherapieALL, rezidiviert oder therapierefraktärALL bei Frail Patienten, ErstlinieALL bei Frail Patienten, Ph/BCR-ABL+, ErstlinieB-/T-ALL, Ph/BCR-ABL-, 18-59 Jahre, ECOG < 4B-ALL, CD19+ rezidivierte oder refraktäre B-ALL, Lymphodepletion vor CAR T-Zell TherapieB-ALL, Ph/BCR-ABL+, 18-59 Jahre, ECOG < 4B-Vorläufer ALL, mit MRD > 0,1%, nach Chemotherapie B/T-ALL, Ph/BCR-ABL-, 18-59 Jahre, ECOG < 4Hochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, ErstlinieHochmaligne B-ALL bei Erwachsenen, RezidivtherapieHochmaligne B-ALL und B-NHL bei Erwachsenen, Erstlinieneudiagnostizierte akute lymphatische Leukämie, Ph+/BCR-ABL+, ECOG 0-1Primär therapierefraktäres oder rezidiviertes B-NHL oder B-ALL, <21 Jahre, ECOG 0-2refraktäre oder rezidivierende ALL, BCR-ABL/Ph negativ, Blasten > 5%, ECOG 0-2rezidivierende oder refraktäre ALL, CD-22+, ECOG 0-2T-ALL, 18-59 Jahre, ECOG < 3T-ALL, 18-59 Jahre, ECOG < 4T-ALL, erstes Rezidiv, 15-55 J.T-ALL, Ph/BCR-ABL-, 18-59 Jahre, ECOG < 4T-ALL, therapierefraktär oder rezidiviert, unter 55 J., intensiv behandelbarT-ALL/LBL, therapierefraktär oder rezidiviertT-ALL/T-LBL, therapierefraktär oder rezidiviertOriginAbramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine at the University of PennsylvaniaAnderson Cancer Center, Houston, TX, USACancer Research UK Centre, University of Southampton, UK, SABRINA StudieDepartment of Leukemia, University of Texas M.D. Anderson Cancer CenterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Cancer and Leukemia Group B study 19801Department of Medicine II, Goethe University Hospital, Frankfurt, GermanyDepartment of Translational and Precision Medicine, Sapienza University of RomeDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaGerman Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2003German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2017GMALL StudieGMALL Therapieempfehlung Frail ALL 2008Group for Research on Adult Acute Lymphoblastic Leukemia, GRAAL 2014/B und TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/B/T und GRAAPHGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/B und TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/ TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAAPH 2014Memorial Hospital of South Bend, South BendPerelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, ELIANA trialThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA, ENDEVOL regimenThe University of Texas MD Anderson Cancer Center, Houston, USAUniversity Hospital, Frankfurt, GermanyUniversity of Texas, MD Anderson Cancer Center, Houston, INO-VATEProtocols in Revision 118 protocols foundBlinatumomab (9/28), Acute Lymphoblastic Leukaemia, Cycle 1 (PID107 V2.1)Blinatumomab (9/28), ALL/NHL, cycle 1 (PID2117 V1.1)Blinatumomab 15, Acute Lymphoblastic Leukaemia, MRD positive (PID1140 V2.0)Blinatumomab 28, Acute Lymphoblastic Leukaemia, maintenance (PID313 V2.0)Blinatumomab 28, Acute Lymphoblastic Leukaemia, Cycle 2-5 (PID68 V2.1)Blinatumomab 28, ALL/NHL, cycle 2-4 (PID2118 V1.1)CLAEG - Cladribine 0.2 / Etoposide 60 / Cytarabine 1500, T- Acute Lymphoblastic Leukaemia (PID1907 V1.0)Clofarabin 10 / Cyclophosphamide 600, B/T-Acute Lymphoblastic Leukemia (PID2269 V1.0)Clofarabin 40, B/T-Acute Lymphoblastic Leukemia (PID2270 V1.0)Cytarabine 40 / Dexamethasone 4 / Methotrexate 15, intrathecal, CNS Prophylaxis, Malignant Meningitis (PID602 V2.0)Cytarabine 500 / Etoposide 150, Acute Lymphoblastic Leukaemia, Lymphodepletion (PID1832 V1.0)Cytarabine 500 / Methotrexate 250 / Inotuzumab Ozogamicin 0.3 / Rituximab 375, ALL/NHL, cycle 2,4 (PID2097 V1.1)Fludarabine 30 / Cyclophosphamide 500, Acute Lymphoblastic Leukaemia, Lymphodepletion (PID1831 V1.0)GMALL - ALL - Frail patients, maintenance (week 14) (PID105 V1.0)GMALL - ALL - Frail patients, maintenance option Cyclophosphamide (week 18,26,34,42,50) (PID85 V1.0)GMALL - ALL - Frail patients, maintenance option Vincristine (week 18,26,34,42,50) (PID84 V1.0)GMALL - ALL - Frail patients, induction (PID103 V1.0)GMALL - ALL - Frail patients, reinduction, week 10 (PID104 V1.0)GMALL - ALL - Frail patients, Pre-phase, all risk groups (PID102 V1.0)GMALL - ALL - Frail, Induction + Maintenance, Ph/BCR-ABL+ (PID106 V1.0)GMALL 08/2013 - ALL maintenance (week 40-51 and month 21-30), 56 - 75 years (PID720 V2.0)GMALL 08/2013 - ALL maintenance (week 40-51 and month 21-30), 56 - 75 years, Ph/BCR-ABL+ (PID2139 V1.0)GMALL 08/2013 - ALL maintenance (week 52 to month 20), 56 - 75 years (PID721 V2.1)GMALL 08/2013 - ALL maintenance (week 52 to month 20), 56 - 75 years, Ph/BCR-ABL+ (PID662 V1.0)GMALL 08/2013 - ALL maintenance, 18 - 55 years old (PID638 V2.1)GMALL 08/2013 - ALL/LBL Consolidation IV (Week 30), 56 - 75 years (PID1097 V1.0)GMALL 08/2013 - ALL/LBL Induction (Day 6), 56 - 75 years, Ph/BCR-ABL+ (PID1103 V1.1)GMALL 08/2013 - ALL/LBL Induction I (Day 6), 18 - 55 years, all risk groups (PID592 V2.0)GMALL 08/2013 - ALL/LBL Induction I (Day 6), 56 - 75 years (PID1087 V1.1)GMALL 08/2013 - ALL/LBL Induction II (Day 20), 56 - 75 years (PID1088 V1.1)GMALL 08/2013 - ALL/LBL consolidation I (day 60), 18 - 55 years, all risk groups (PID595 V3.0)GMALL 08/2013 - ALL/LBL consolidation I (week 8), 56 - 75 years, Ph/BCR-ABL+ (PID639 V1.0)GMALL 08/2013 - ALL/LBL Consolidation I (Week 9), 56 - 75 years (PID1086 V1.0)GMALL 08/2013 - ALL/LBL Consolidation II (Week 14), 18 - 55 years (PID1098 V1.0)GMALL 08/2013 - ALL/LBL consolidation II (week 14), 56 - 75 years, Ph/BCR-ABL+ (PID640 V1.0)GMALL 08/2013 - ALL/LBL Consolidation II (Week 15), 56 - 75 years (PID1091 V1.1)GMALL 08/2013 - ALL/LBL consolidation II in treatment failure/MRD persistence of T-ALL/T-LBL, 18 - 55 years (PID965 V2.0)GMALL 08/2013 - ALL/LBL consolidation III and V (weeks 23, 33), 56 - 75 years, Ph/BCR-ABL+ (PID635 V1.0)GMALL 08/2013 - ALL/LBL consolidation III and V (week 24,34), 56 - 75 yrs (PID1090 V1.1)GMALL 08/2013 - ALL/LBL consolidation IV (week 29), 56 - 75 years, Ph/BCR-ABL+ (PID637 V1.0)GMALL 08/2013 - ALL/LBL Reinduction (Week 18), 56 - 75 years, Ph/BCR-ABL+ (PID709 V1.0)GMALL 08/2013 - ALL/LBL Reinduction (Week 19), 18 - 55 years (PID636 V2.1)GMALL 08/2013 - ALL/LBL Reinduction (Week 19), 56 - 75 years (PID1096 V1.1)GMALL 08/2013 - ALL/LBL Pre-phase, 18 - 55 yrs (PID591 V2.0)GMALL 08/2013 - ALL/LBL Pre-phase, 56 - 75 yrs (PID1085 V1.0)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part A (PID344 V1.2)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part B (PID346 V1.2)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part C (PID347 V1.1)GMALL 08/2013 - B-ALL/NHL 2002 regimen, all ages, Pre-phase (PID345 V1.0)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55, Part C, B-ALL only (PID357 V1.1)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55,Part A, B-ALL only (PID355 V1.1)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55,Part B, B-ALL only (PID356 V1.1)GMALL 08/2013 - B-ALL/NHL 2002 regimen, Rituximab consolidation (PID784 V1.0)GMALL 08/2013-ALL/LBL - ALL Induction II (day 23), 18 - 55 years, all risk groups (PID594 V2.0)GMALL V6/2023 - Nelarabine 1500 / Cyclophosphamide 200, T-ALL (PID2942 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 5 (PID2087 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Ddoxorubicin 50 / Dexamethasone 40) / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 7 (PID2089 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 400, ALL/NHL, Ph/BCR-ABL+, intensification, month 7,19 (PID2113 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 3 (PID2086 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 800, ALL/NHL, Ph/BCR-ABL+, cycle 1 (PID2084 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375, ALL/NHL, cycle 1,3 (PID2061 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40), ALL/NHL, cycle 5,7 (PID2063 V1.0)Inotuzumab Ozogamicin 0.8, Acute Lymphoblastic Leukaemia, Cycle 1 (PID161 V1.0)Inotuzumab Ozogamicin 0.8, Acute Lymphoblastic Leukaemia, Cycle 2-6 (PID145 V1.0)Methotrexate 100 / Peg-asparaginase 2000 / Imatinib 400, ALL/NHL, Ph/BCR-ABL+, intensification, month 6,18 (PID2110 V1.1)Methotrexate 100 / Peg-asparaginase 2000, ALL/NHL, intensification, month 6,18 (PID2074 V1.1)Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 6 (PID2088 V1.1)Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 8 (PID2090 V1.1)Methotrexate 1000 / Cytarabine 3000, ALL/NHL, cycle 6,8 (PID2065 V1.1)Methotrexate 12 / Cytarabine 100, Malignant Meningitis, CNS Prophylaxis (PID2575 V1.0)Methotrexate 15 / Cytarabine 30, Burkitt's Lymphoma (PID2240 V1.1)Methotrexate 15, Malignant Meningitis, CNS Prophylaxis (PID876 V1.1)Mini-hyperCVD (Cyclophosphamide 150 / Vincristine 2 / Dexamethasone 20) / Inotuzumab Ozogamicin (0.6/0.3) / Rituximab 375, ALL/NHL, cycle 1 (PID2098 V1.0)Mini-hyperCVD (Cyclophosphamide 150 / Vincristine 2 / Dexamethasone 20) / Inotuzumab Ozogamicin 0.3 / Rituximab 375, ALL/NHL, cycle 3 (PID2099 V1.0)Nelarabine 1500, T-ALL/T-LBL (PID1922 V1.0)Nelarabine 650 / Etoposide 100 / Cyclophosphamide 440, T-ALL/T-LBL (PID1926 V1.0)Nelarabine 650 / Peg-asparaginase 1500, T-ALL, maintenance, month 6, 7 (PID2083 V1.1)POMP (Mercaptopurine 50 / Methotrexate 10), ALL/NHL, maintenance, month 13-36, variant 1 (PID2120 V1.0)POMP (Mercaptopurine 50 / Vincristine 2 / Methotrexate 10 / Prednisolone 50), ALL/NHL, maintenance, month 1-12, variant 1 (PID2119 V1.0)POMP (Mercaptopurine 50 / Vincristine 2 / Methotrexate 20 / Prednisolone 200), ALL/NHL, maintenance, month 1-5,8-17,20-30 (PID2072 V1.0)Prednisolone 60 / Dasatinib 140 - Blinatumomab 28 / Dasatinib 140, Acute Lymphoblastic Leukaemia, Part A (PID1678 V1.0)Prednisolone 60 / Dasatinib 140 - Blinatumomab 28 / Dasatinib 140, Acute Lymphoblastic Leukaemia, Part B (PID1679 V1.0)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 3, Burkitt's Lymphoma, Cycle 1-2. (PID2223 V1.0)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 3, Burkitt's Lymphoma, Cycle 3. (PID2224 V1.0)Rituximab 1400, single dose subcutaneous (PID310 V2.0)Rituximab 375 / Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 2,4 (PID2085 V1.1)Rituximab 375 / Methotrexate 1000 / Cytarabine 3000, ALL/NHL, cycle 2,4 (PID2064 V1.1)GRAALL study - B- ALL maintenance, month 2,4,6-12, 18 - 59 years (PID985 V1.0)GRAALL study - B-/T- ALL consolidation block S1, S4, S7 (day 1-14), 18 - 59 years (PID980 V1.0)GRAALL study - B-/T-ALL maintenance, month 1,3,5, 18 - 59 years (PID983 V1.0)GRAALL study - B-/T-ALL maintenance, month 13-24, 18 - 59 years (PID984 V1.0)GRAALL Study - B-/T-ALL Induction, 18 - 44 Years (PID978 V1.0)GRAALL study - B-/T-ALL induction, 45- 59 years (PID1027 V1.0)GRAALL study - B-/T-ALL consolidation block S2, S5, S8 (day 15-28), 18 - 44 years (PID981 V1.0)GRAALL study - B-/T-ALL consolidation block S2, S5, S8 (day 15-28), 45 - 59 years (PID1028 V1.0)GRAALL study - B-/T-ALL consolidation block S3, S6, S9 (day 29-35), 18 - 59 years (PID982 V1.0)Study GRAALL - B-/T-ALL salvage, 18-59 (PID979 V1.0)GRAALL Study - B-/T-ALL Late Intensification, 18 - 44 years for patients without salvage therapy (PID986 V1.0)GRAALL Study - B-/T-ALL Late Intensification, 18 - 59 for Patients with salvage (PID988 V1.0)GRAALL Study - B-/T-ALL Late Intensification, 45 - 59 years for patients without salvage therapy (PID1032 V1.0)GRAALL study - B-/T-ALL stand-by block, 18-59 (PID987 V1.0)Study GRAALL - B-/T-ALL and GRAAPH - B-ALL Pre-phase (PID992 V1.0)Study GRAALL - B-/T-ALL Waiting Block 1 and 3, 18-59 (PID1071 V1.0)GRAALL Study - B-/T-ALL Waiting Block 2 and 4, 18-59 (PID1074 V1.0)Study GRAALL - B-/T-ALL, CNS Treatment (PID1029 V1.0)GRAALL study - T- ALL consolidation block T5, T8 (day 22-35), 18 - 59 years (PID990 V1.0)GRAALL study - T-ALL maintenance, month 2,4,6, 18 - 59 years (PID994 V1.0)GRAALL study - T-ALL maintenance, month 7-12, 18 - 59 years (PID993 V1.0)GRAALL study - T-ALL consolidation block T4, T7 (day 1-21), 18 - 59 years (PID989 V1.0)GRAALL study - T-ALL consolidation block T6, T9 (day 36-49), 18 - 59 years (PID991 V1.0)GRAAPH study - B-ALL, interphase, Ph/BCR-ABL+ (PID1072 V1.0)GRAAPH Study - B-ALL, Cycle 1, Ph/BCR-ABL+ (PID996 V1.0)GRAAPH study - B-ALL, cycle 2 and 4, arm A, Ph/BCR-ABL+, 18-44 years (PID998 V1.0)GRAAPH study - B-ALL, cycle 2 and 4, arm A, Ph/BCR-ABL+, 45-59 years (PID1073 V1.0)GRAAPH Study - B-ALL, Cycle 2 and 4, Arm B, Ph/BCR-ABL+ (PID999 V1.0)GRAAPH Study - B-ALL, Cycle 3, Ph/BCR-ABL+ (PID997 V1.0)Vincristine 2 / Prednisolone 200 / Imatinib 400, ALL/NHL, maintenance, Ph/BCR-ABL+ (PID2073 V1.0)Vindesin 3 / Methotrexate 1500 / Etoposide 250 / Cytarabine 2000 / Dexamethasone 10, Acute Lymphoblastic Leukaemia (PID2268 V1.1)
